Acute Respiratory Distress Syndrome Clinical Trial
— FEDOXOfficial title:
Feeding the Critically Ill During Phases of Altered Redox Status (FEDOX): a Prospective Randomized Trial
NCT number | NCT03085615 |
Other study ID # | FEDOX |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 15, 2017 |
Est. completion date | October 13, 2018 |
Verified date | April 2019 |
Source | University of Illinois at Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The FEDOX trial is a prospective randomized clinical trial exploring oxidative stress as a
mechanism of harm to explain the negative outcomes found in feeding trials that achieved
caloric exposure commensurate with the nationally recommended guidelines. Due to its impact
on energy metabolism, we will also explore low T3 syndrome's relationship to this mechanism.
Finally, we will explore circadian patterns of diurnal/nocturnal TSH fluctuation as a
potential biomarker to indicate this mechanism of harm has subsided.
This 7-day prospective randomized clinical trial is designed to address the following
specific aims (SA) in ICU patients (n=40) with systemic inflammatory response syndrome.
SA1) Determine whether provision of enteral nutrition (EN) at 100% of levels in Nationally
Recommended Guidelines NRG (25-30 kcals/kg, 100%NRG) early in critical illness increases
reactive oxygen species (ROS) production compared to EN at 40% of NRG levels (10-12 kcals/kg,
40%NRG). Subjects will be fasted overnight and randomized to receive either 100% NRG or
40%NRG for 7 days. Plasma F2-isoprostanes will be measured daily and compared between groups
through repeated measures analysis.
SA2) Determine if EN at 100%NRG interrupts the critical illness induced low T3 syndrome and
subsequently further increases the ROS production compared to 40%NRG. Serum thyroid
parameters (T3, T4, rT3, TSH) with be measured daily and compared between groups as above.
Mediation analysis will be used to determine the proportion of the effect of nutrition group
on F2-isoprostane production explained by each thyroid parameter.
SA3) Determine if the return of diurnal/noctural fluctuations in TSH is associated with
decreased nutrition-induced ROS production. Plasma TSH will be measured twice per day at 0300
and 1800hrs to determine TSH fluctuation. The interaction effect between TSH fluctuation and
nutrition group on F2-isoprostane production will be assessed through repeated measures
analysis. This study provides vital mechanistic insight into the impact of feeding on
oxidative stress during the first week of critical illness, represents an important first
step in determining the safest timing and dosage of nutrition support, and sets the
foundation for future larger clinical trials on these topics.
Status | Completed |
Enrollment | 35 |
Est. completion date | October 13, 2018 |
Est. primary completion date | June 4, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patients (>18 years) admitted to RUMC MICU who are able to receive EN, who have two consecutive white blood cell lab values above 12,000/mm^3 or below 4,000/mm^3 plus at least one of the following 3 criteria met for at the past 12 hours will be eligible for participation. Criteria: (1) a respiratory rate greater than 20 breaths per minute or PaCO2 less than 32mmHg, (2) a heart rate greater than 90 beats per minute, or (3) a temperature greater than 100.4F or less than 96.8F. Exclusion Criteria: Patients will be excluded if the are pregnant, have documented neurologic disease prior to admission that interferes with the capacity to give informed consent or do not require EN for their nutritional care. |
Country | Name | City | State |
---|---|---|---|
United States | Rush University Medical Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Illinois at Chicago | American Society for Parenteral and Enteral Nutrition, Rush University Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Daily Plasma F2-Isoprostane levels | Plasma maximum concentration of F2-isoprostanes will be quantified through liquid chromatography tandem mass spectrometry (LC-MS/MS) of plasma using a Q-trap mass spectrometer. | 7 days | |
Secondary | Thyroid Stimulating Hormone (TSH) | TSH will be measured twice per day using commercially available immuno-assay kits. | 7 days | |
Secondary | Triiodothyronine (T3) | T3 will be measured daily using commercially available immuno-assay kits. | 7 days | |
Secondary | Thyroxine (T4) | T4 will be measured daily using commercially available immuno-assay kits. | 7 days | |
Secondary | Reverse Triiodothyronine (rT3) | rT3 will be measured daily using commercially available immuno-assay kits. | 7 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A |